Nasdaq
$33.20▲ 0.18%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.01BShares out 30.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
34- 3d agoAfter-hours26.10.22 05:184Ownership#●●●
CASTLE BIOSCIENCES INC
Derek J. Maetzold, an executive at Castle Biosciences, reported a change in beneficial ownership of securities as of October 19, 2026. This filing serves as a standard disclosure regarding the insider's equity holdings.…more
$33.20+0.18%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14After-hours26.10.15 05:064Ownership
CASTLE BIOSCIENCES INC
Castle Biosciences executive Juvenal Tobin W reported a change in beneficial ownership of company securities as of October 12, 2026. This filing serves as a Form 4 statement regarding the insider's stock holdings.…more
$33.20+0.18%vs prev closeView filingShare - 10.13Pre-market26.10.13 21:52144Ownership
CASTLE BIOSCIENCES INC
Juvenal Tobin W, an insider at Castle Biosciences, has filed an SEC Form 144 to report a proposed sale of company shares. This is a standard filing disclosing the insider's plan to dispose of their holdings.…more
$33.20+0.18%vs prev closeView filingShare
33 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12After-hours26.10.13 05:34#●●●#●●●
Castle Biosciences to Present New TissueCypher Data at ACG 2026
Castle Biosciences will present data from three studies at the ACG 2026 meeting, highlighting the clinical utility of its TissueCypher Barrett's Esophagus test. The findings demonstrate how the test provides additional risk assessment information beyond traditional biopsy to support patient management.…more
$33.20+0.18%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.30After-hours26.10.01 05:32
●●●●●●●● ●●●●● ●●●●●●
Castle Biosciences will present new clinical data at the EADV Congress demonstrating the efficacy of its DecisionDx-Melanoma test. The findings support the test's ability to guide surgical decisions and identify patients at higher risk of recurrence.…more
$33.20+0.18%vs prev closeShareBenzinga - 9.24After-hours26.09.25 05:32
●●●●●●●● ●●●●● ●●●●●●
Castle Biosciences published a new study demonstrating significant patient interest in molecular testing to guide systemic therapy for atopic dermatitis. While the findings support the clinical need for the company's AdvanceAD-Tx test, no specific financial impact or commercial contracts were disclosed.…more
$33.20+0.18%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report